Wedbush analyst Andreas Argyrides reiterated a Buy rating on United Therapeutics (UTHR – Research Report) today and set a price target of $307.00. The company’s shares opened today at $227.30.
Argyrides covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Aquestive Therapeutics, and MoonLake Immunotherapeutics. According to TipRanks, Argyrides has an average return of 2.3% and a 33.59% success rate on recommended stocks.
In addition to Wedbush, United Therapeutics also received a Buy from Ladenburg Thalmann & Co.’s Matthew Kaplan in a report issued on August 3. However, on the same day, Goldman Sachs maintained a Sell rating on United Therapeutics (NASDAQ: UTHR).
See Insiders’ Hot Stocks on TipRanks >>
Based on United Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $596.5 million and a net profit of $259.2 million. In comparison, last year the company earned a revenue of $466.9 million and had a net profit of $116 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Read More on UTHR:
- United Therapeutics price target raised to $268 from $256 at Ladenburg
- United Therapeutics reports Q2 EPS $5.24, consensus $4.50
- Liquidia says Federal Circuit affirms district court rulings in patent fight
- United Therapeutics says wins appeal in dry powder inhaler patent litigation
- Argus sees upside for United Therapeutics over the next year
